Does Sermorelin Help Kids Grow Taller?

One of the most common questions parents ask when researching growth treatments is:

“Does Sermorelin help kids grow taller?”

The short answer is:

Sometimes—but it depends on why a child is growing slowly.

Sermorelin is not a magic height treatment, nor does it directly make children taller overnight. Instead, sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release the body's own growth hormone.

Historical pediatric clinical studies found that GHRH/sermorelin treatment increased growth velocity in some children with growth hormone deficiency and in selected children with short stature.[1-4]

However, response varies considerably. Sermorelin requires a pituitary gland capable of producing and releasing growth hormone when stimulated. Children with severe pituitary dysfunction may therefore respond differently than children with preserved pituitary function.

Another important limitation is that the pediatric sermorelin literature is relatively old and much smaller than the evidence base supporting recombinant human growth hormone (HGH). A review of pediatric sermorelin studies found evidence of increased height velocity and catch-up growth in some children, but noted that its effect on final adult height had not been established.[1]

Understanding how growth works, which children may be more likely to respond, and what realistic expectations look like can help families make informed decisions about treatment.

Understanding How Children Grow

Before discussing whether Sermorelin can help children grow taller, it is important to understand how normal growth occurs.

Height growth is controlled by a complex hormonal pathway involving the hypothalamus, pituitary gland, growth hormone, IGF-1, and growth plates.[5]

Step 1: The Brain Releases Growth Hormone-Releasing Hormone (GHRH)

The hypothalamus produces growth hormone-releasing hormone, commonly called GHRH.

GHRH signals specialized cells in the pituitary gland to release growth hormone.

Step 2: The Pituitary Releases Growth Hormone

The pituitary gland responds to GHRH by releasing growth hormone (GH).

Growth hormone is naturally secreted in pulses rather than at a constant level throughout the day.

Step 3: Growth Hormone Influences IGF-1 Production

Growth hormone stimulates production of insulin-like growth factor-1 (IGF-1), particularly in the liver and other tissues.

IGF-1 is an important mediator of childhood linear growth.

Children with low IGF-1 levels may demonstrate slower growth, but a low IGF-1 level does not automatically diagnose growth hormone deficiency. Nutrition, age, pubertal stage, chronic illness, liver function, thyroid status, and other factors can influence IGF-1.[5]

Step 4: Growth Plates Lengthen Bones

GH and IGF-1 influence cartilage cells within the growth plates of long bones, contributing to linear growth.

As long as growth plates remain open, additional long-bone growth may be possible.

Once growth plates have fused, treatments that influence the GH/IGF-1 pathway cannot meaningfully lengthen the long bones.

Problems occurring at different points in this pathway can affect growth velocity and eventual adult height.

What Is Sermorelin?

Sermorelin is a synthetic peptide corresponding to the biologically active portion of human growth hormone-releasing hormone.

Rather than supplying growth hormone directly, Sermorelin stimulates the pituitary gland to release endogenous growth hormone.[1]

Because it works through the body's GH regulatory pathway, some families exploring Sermorelin for children are interested in its ability to stimulate endogenous GH rather than directly administer recombinant growth hormone.

The proposed treatment pathway is:

Sermorelin → Pituitary stimulation → Growth hormone release → IGF-1 signaling → Growth plate activity

Sermorelin may:

• Stimulate endogenous growth hormone secretion
• Increase GH signaling in responsive patients
• Increase IGF-1 in some children
• Influence growth velocity when the GH/IGF-1 pathway is responsive

However, results depend heavily on the child's underlying diagnosis and pituitary function.

Is Sermorelin the Same as HGH?

No.

This is one of the most important distinctions for parents to understand.

Sermorelin stimulates the pituitary gland to release growth hormone.

Recombinant HGH provides growth hormone directly.

That difference becomes particularly important in children with growth hormone deficiency.

If the pituitary retains the ability to produce GH but endogenous secretion is inadequate, stimulating the gland may increase GH release.

If pituitary GH production is severely impaired, however, additional stimulation may not generate enough growth hormone.

Recombinant HGH bypasses this step because growth hormone itself is administered.

The two therapies therefore should not be considered interchangeable simply because they both influence the GH/IGF-1 pathway.

Can Sermorelin Actually Help Children Grow Taller?

Pediatric research suggests that some children can experience increased growth velocity during treatment with sermorelin/GHRH.[1-4]

One of the largest studies involved 110 previously untreated prepubertal children with growth hormone deficiency who received once-daily subcutaneous GHRH-(1-29), or sermorelin, for up to one year.

Among children included in the efficacy analysis, average growth velocity increased from approximately 4.1 cm/year before treatment to 8.0 cm/year after six months and 7.2 cm/year after 12 months.[2]

Another study involving short prepubertal children reported an increase in average height velocity from approximately 4.8 cm/year before treatment to 7.2 cm/year after 12 months of GHRH therapy.[3]

These findings demonstrate an important point:

Sermorelin/GHRH can increase linear growth in selected children.

However, that does not mean every short child will respond.

It also does not establish that sermorelin produces the same long-term height outcome as recombinant HGH.

A review of pediatric sermorelin research concluded that available evidence suggested treatment could produce catch-up growth in some prepubertal children with idiopathic GHD, but the effect on final adult height remained undetermined.[1]

Does Faster Growth Mean a Taller Adult Height?

Not necessarily.

This distinction is extremely important.

Growth velocity describes how quickly a child is growing during a particular period.

Final adult height describes the height reached after skeletal growth is complete.

A medication can increase short-term growth velocity without necessarily adding the same amount to final adult height.

For example, one study of children with idiopathic short stature found that GHRH therapy increased growth velocity during treatment. After treatment was discontinued, however, growth rates generally returned toward pretreatment levels.[4]

Therefore, parents should be cautious about interpreting a temporary increase in growth rate as a guaranteed number of additional inches in adulthood.

The long-term outcome depends on:

• Diagnosis
• Age
• Bone age
• Pubertal stage
• Duration of treatment
• Growth response
• Genetics
• Remaining growth potential
• Skeletal maturation

Which Children May Be More Likely to Respond to Sermorelin?

Response depends heavily on the cause of poor growth.

Historical pediatric research suggests that children with a functioning pituitary capable of responding to GHRH stimulation may be more likely to demonstrate increased GH secretion and growth velocity.[1-4]

Potential considerations include:

Preserved Pituitary Function

The pituitary gland must retain the ability to produce and release growth hormone when stimulated.

This is fundamental to sermorelin's mechanism.

Slower-Than-Expected Growth Velocity

Children experiencing poor growth velocity warrant evaluation to determine why growth has slowed.

Slow growth itself does not establish that sermorelin is appropriate, but it may indicate the need to investigate the GH/IGF-1 pathway and other causes of growth failure.

Evidence of Abnormal GH/IGF-1 Signaling

Growth hormone and IGF-1 testing may provide useful information when interpreted alongside the child's growth pattern, nutrition, puberty, bone age, and medical history.[5]

Remaining Growth Potential

Growth plates must remain open for treatment to influence linear height.

A child with substantial skeletal growth remaining has fundamentally different treatment potential from an adolescent approaching growth plate fusion.

What About Mild Growth Delay?

This requires more nuance than simply saying that children with “mild growth delay” may benefit from sermorelin.

Mild short stature can occur for many reasons.

A child may have:

• Familial short stature
• Constitutional growth delay
• Delayed puberty
• Nutritional problems
• Thyroid disease
• Chronic illness
• Idiopathic short stature
• Growth hormone deficiency
• Another endocrine or genetic condition

The treatment depends on the cause.

For example, children with constitutional growth delay often mature later than their peers and may ultimately reach a height consistent with their genetic potential without GH-directed therapy.

Therefore, being short or developing later than classmates does not by itself mean that a child needs sermorelin.

What Happens When Growth Velocity Improves?

When treatment successfully improves GH signaling in a responsive child, the most important measurable change is an increase in linear growth velocity.

Height gains occur gradually over months and years.

Clinicians may observe:

Faster Yearly Growth

A child who had previously demonstrated abnormally slow growth may begin growing at a faster annualized rate.

Changes in Growth Chart Progression

Depending on the response, children may gradually change position on growth chart percentiles.

Changes in IGF-1

IGF-1 may increase in response to greater GH signaling, although laboratory changes should always be interpreted alongside actual linear growth.

The goal should not simply be to increase an IGF-1 laboratory value.

The clinically important question is whether the child demonstrates appropriate, sustained linear growth without excessive hormonal exposure or disproportionate skeletal maturation.

How Long Does It Take to See Results?

One of the biggest misconceptions about pediatric growth treatment is that height should increase immediately.

In reality, linear growth takes time.

Historical sermorelin studies assessed children over periods such as 6 and 12 months rather than judging effectiveness after only a few weeks.[2-4]

First Several Months

Early monitoring may evaluate:

• Treatment tolerance
• Adherence
• IGF-1 when appropriate
• Height measurements
• Growth velocity trends

Small changes in height over very short intervals can be difficult to interpret because measurement error can significantly affect the calculation.

Around 6–12 Months

Growth velocity becomes easier to evaluate over longer intervals.

The multicenter pediatric GHRH study demonstrated measurable increases in average growth velocity at six months and 12 months.[2]

Longer-Term Treatment

If treatment continues, clinicians should repeatedly determine whether the child is demonstrating sufficient benefit to justify ongoing therapy.

Long-term decisions should consider both growth velocity and skeletal maturation.

How Much Taller Can Sermorelin Make a Child?

There is no scientifically defensible number of inches that can be promised.

The pediatric literature provides evidence that sermorelin/GHRH can increase growth velocity in selected children, but data establishing its effect on final adult height are limited.[1]

A child's eventual height depends on numerous factors, including:

• Genetics
• Baseline height
• Diagnosis
• Age
• Bone age
• Pubertal timing
• Nutrition
• Growth velocity
• Treatment response
• Duration of treatment
• Remaining growth plate potential

Any clinic promising that sermorelin will add a specific number of inches to every child's final height is going beyond what the available evidence can support.

When Sermorelin Is Less Likely to Help

Although Sermorelin may increase growth velocity in selected children, there are situations where its mechanism is less likely to produce meaningful additional height.

Severe Growth Hormone Deficiency or Pituitary Dysfunction

Children with significant growth hormone deficiency related to an inability of the pituitary to produce adequate GH may not respond sufficiently to pituitary stimulation.

Because sermorelin depends on endogenous GH production, preserved pituitary responsiveness matters.[1]

In established pediatric GHD, recombinant growth hormone has a much larger modern evidence base and is the standard replacement therapy.[5,6]

Advanced Growth Plate Maturation

Growth plates must remain open for additional long-bone growth.

As skeletal maturation progresses, the remaining opportunity to influence height decreases.

Normal Familial Short Stature

Some children are naturally shorter because of genetics while maintaining normal growth velocity.

Being below average height does not automatically indicate a hormonal disorder.

Completed Puberty and Fused Growth Plates

Once growth plates have fused, sermorelin cannot reopen them.

Increasing GH secretion after growth plate fusion does not meaningfully lengthen the long bones.

Why Bone Age Is So Important

One of the most valuable tools used during growth evaluations is a bone age test.

Bone age provides information about skeletal maturation and can help clinicians estimate:

• Growth plate maturity
• Remaining growth potential
• Whether skeletal maturation is delayed or advanced
• How chronological age compares with skeletal age
• Predicted adult height when interpreted with other growth data

Children with delayed bone age may have more growth opportunity remaining than chronological age alone suggests.

However, delayed bone age does not automatically mean that a child needs sermorelin or HGH.

Constitutional growth delay, endocrine disorders, chronic disease, nutritional issues, and other conditions can affect skeletal maturation.[5]

Bone age is therefore one piece of a broader growth evaluation.

Why Proper Evaluation Matters

One of the biggest mistakes families can make is assuming that all short stature has the same cause.

Two children of identical height may have completely different diagnoses.

Potential causes include:

• idiopathic short stature
• Growth hormone deficiency
• constitutional growth delay
• pituitary disorders
• Delayed puberty
• Familial short stature
• Nutritional concerns
• Thyroid disease
• Gastrointestinal disease
• Chronic medical conditions
• Genetic or skeletal disorders

International expert guidance emphasizes that medical history, physical examination, accurate growth measurements, and auxology remain central to determining why a child is short.[5]

Because treatment differs substantially among these conditions, proper evaluation should occur before considering sermorelin or any other growth-promoting medication.

What Testing Is Usually Performed?

A comprehensive pediatric growth evaluation may include several components.

Not every child requires every test.

Growth Chart Analysis

Long-term height and weight measurements can show whether a child is maintaining their expected growth trajectory or crossing percentiles downward.

Growth Velocity Assessment

Growth velocity should be calculated from accurate measurements taken over an appropriate interval.

Parents sometimes become concerned when a child is growing less than 2 inches per year.

However, normal growth velocity varies with age, sex, and pubertal stage, so a universal two-inch cutoff should not be used by itself to diagnose abnormal growth.

Bone Age Imaging

A hand and wrist X-ray can help assess skeletal maturity and remaining growth potential.

Hormone and Laboratory Testing

Depending on the child's history and growth pattern, testing may include:

• IGF-1
• IGFBP-3
• Thyroid studies
• Complete blood count
• Metabolic testing
• Screening for nutritional or chronic medical conditions
• Additional endocrine testing when appropriate

Growth hormone is secreted in pulses, so a single random GH blood level generally cannot diagnose growth hormone deficiency.[5]

When GHD is suspected, more specialized testing may be required.

Pituitary Imaging

MRI is not necessary for every short child.

It may be considered when clinical or laboratory findings suggest pituitary or hypothalamic disease.

Adult Height Prediction

Many parents ask:

How tall will my child be?

Providers may use:

• Current height
• Growth velocity
• Parental heights
• Pubertal stage
• Bone age

to estimate adult height potential.

Height predictions are estimates rather than guarantees.

Sermorelin vs. HGH for Height: Which Has More Evidence?

This is an important question for parents considering treatment.

Sermorelin has legitimate pediatric research behind it.

Historical studies demonstrate that GHRH/sermorelin can increase growth velocity in selected children.[1-4]

However, recombinant human growth hormone has been studied much more extensively and has established pediatric indications for disorders including growth hormone deficiency and certain other growth conditions.[5,6]

The pediatric sermorelin literature has several limitations:

• Many studies were performed decades ago
• Study populations were relatively small
• Treatment protocols varied
• Response varied between children
• Final adult-height data are limited
• Direct modern comparisons with recombinant HGH are lacking

A review specifically examining sermorelin noted that increases in height velocity with some sermorelin regimens were lower than those observed with somatropin and that the effect of long-term sermorelin treatment on final adult height remained unknown.[1]

Therefore, sermorelin should not be presented as proven to be equivalent or superior to HGH for increasing final height.

Is Sermorelin FDA-Approved for Increasing Height in Children Today?

Sermorelin has an important pediatric history.

Sermorelin acetate was previously marketed as Geref and was studied and used in pediatric growth hormone deficiency.

However, historical pediatric approval and research should not be confused with the regulatory status of currently available compounded sermorelin products.

Parents considering sermorelin should ask:

• What exact medication is being prescribed?
• Is it FDA-approved for this indication?
• Is it a compounded medication?
• What evidence supports its use for my child's diagnosis?
• Why is it being considered instead of an established alternative?

These are reasonable questions whenever a medication is being considered for pediatric growth.

Why Early Evaluation Can Matter

One of the most important concepts in pediatric growth medicine is timing.

Growth opportunity decreases as growth plates mature.

Children evaluated earlier may have:

• More remaining growth potential
• More time to determine the cause of slow growth
• More time for observation when treatment is unnecessary
• More treatment options when a true disorder is identified
• More time to monitor growth velocity

Parents frequently seek answers after wondering:

• is my child too short for their age
• why is my child the shortest in class
• how tall will my child be

These concerns can be reasonable reasons to review a child's growth chart and determine whether further evaluation is warranted.

Early evaluation does not necessarily mean early medication.

Sometimes the appropriate recommendation is simply continued monitoring.

Questions Parents Should Ask Before Starting Sermorelin

Before considering treatment, parents may want to ask:

• Why is my child growing slowly?
• What is my child's annual growth velocity?
• Is my child crossing growth percentiles?
• What is my child's bone age?
• How much growth potential remains?
• Is puberty early, normal, or delayed?
• Is IGF-1 appropriate for age and pubertal stage?
• Is there evidence of growth hormone deficiency?
• Does the pituitary appear capable of responding to GHRH stimulation?
• Why is sermorelin being considered?
• What evidence supports sermorelin for my child's specific diagnosis?
• Why is sermorelin being considered instead of observation or recombinant HGH?
• How will we determine whether treatment is working?
• How frequently will height and laboratory values be monitored?
• When would treatment be stopped because of inadequate response?

These questions help shift the conversation from simply asking “Can sermorelin make my child taller?” to determining whether the treatment makes medical sense for that individual child.

The Bottom Line

So, does Sermorelin help kids grow taller?

For certain children, sermorelin can increase growth velocity.

Historical pediatric studies demonstrated increased growth rates in selected children receiving GHRH/sermorelin therapy.[1-4]

However, this does not mean sermorelin will make every short child taller.

The available evidence does not establish a predictable number of additional inches or prove that sermorelin produces the same final adult-height outcomes as recombinant HGH.[1]

Sermorelin depends on a functioning pituitary gland capable of releasing growth hormone when stimulated. It also requires remaining growth plate potential if the goal is increased linear height.

The most important step is therefore identifying why a child is growing slowly.

Through growth chart analysis, growth velocity calculation, bone age assessment, medical history, physical examination, and appropriate laboratory testing, clinicians can determine whether a child has a normal growth pattern, constitutional delay, growth hormone deficiency, idiopathic short stature, another medical condition, or a growth pattern that requires continued observation.[5]

Treatment should follow the diagnosis—not the other way around.

Medically Reviewed By

Dr. Devin Stone, ND

Dr. Devin Stone is a Doctor of Naturopathic Medicine and founder of HGHforChildren.com. His clinical focus includes pediatric growth evaluation, short stature assessment, delayed bone age, constitutional growth delay, IGF-1 interpretation, growth hormone signaling, and evidence-informed treatment planning for children and adolescents with growth concerns.

Through HGHforChildren.com, Dr. Stone helps families understand childhood growth patterns, growth velocity, bone age, height prediction, laboratory evaluation, and potential treatment options when medically appropriate.

Medical References & Clinical Evidence

1. Prakash A, Goa KL. Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007.
This review specifically evaluates sermorelin in pediatric growth hormone deficiency. It reports increased height velocity and catch-up growth in some treated children while emphasizing that effects on final adult height had not been established.

2. Thorner MO, et al.; Geref International Study Group. Once Daily Subcutaneous Growth Hormone-Releasing Hormone Therapy Accelerates Growth in Growth Hormone-Deficient Children During the First Year of Therapy. Journal of Clinical Endocrinology & Metabolism. 1996.
This multicenter study evaluated 110 previously untreated prepubertal children with GHD. Mean height velocity increased from approximately 4.1 cm/year before treatment to 8.0 cm/year at six months and 7.2 cm/year at 12 months.

3. Kirk JMW, Trainer PJ, Majrowski WH, et al. Treatment with GHRH(1-29)NH2 in Children with Idiopathic Short Stature Induces a Sustained Increase in Growth Velocity. Clinical Endocrinology. 1994;41(4):487-493. doi:10.1111/j.1365-2265.1994.tb02580.x.
This study reported an increase in mean growth velocity from approximately 4.8 cm/year before treatment to 7.2 cm/year after 12 months of GHRH therapy in short prepubertal children.

4. Low LCK, et al. Growth During and After a Trial of Growth Hormone Releasing Hormone 1-29 in Children with Idiopathic Short Stature or Growth Hormone Neurosecretory Dysfunction. 2000.
The study found increased growth rates during GHRH therapy in short, slowly growing children. Overall growth rates subsequently returned toward pretreatment rates after therapy was discontinued.

5. Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics. 2019;92(1):1-14. doi:10.1159/000502231.
International expert guidance covering the evaluation of short stature, auxology, growth velocity, GH/IGF-1 assessment, growth hormone stimulation testing, genetics, and treatment considerations.

6. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics. 2016;86(6):361-397. doi:10.1159/000452150.
Pediatric Endocrine Society clinical guideline addressing diagnosis and treatment decisions for GHD, idiopathic short stature, and primary IGF-I deficiency.